in vivo News and Research

RSS

Penn study discovers a targetable vulnerability in clear cell renal cell carcinoma

Clear cell renal cell carcinoma (ccRCC) cells can be destroyed and kept from multiplying by inhibiting the HDL cholesterol receptor SCARB1, according to research from the Perelman School of Medicine at the University of Pennsylvania.

10 Aug 2021

Antiviral activity of lipid-modified remdesivir in comparison to common remdesivir

In new research, scientists evaluated the broad-spectrum antiviral activity of ODBG-P-RVn, an orally available, lipid-modified monophosphate prodrug of the remdesivir parent nucleoside (GS-441524) against viruses that cause diseases of human public health concern, including SARS-CoV-2.

10 Aug 2021

SARS-CoV-2 variants and their ability to infect mice

A new study published on the bioRxiv* preprint server has conducted in silico studies along with in vitro, in vivo, and in situ observations and indicated the mouse adaptation of SARS-CoV-2.

10 Aug 2021

PTEN nuclear translocation plays a key role in neuronal injury following hypoxia-ischemia

Aging-US published "PTEN nuclear translocation enhances neuronal injury after hypoxia-ischemia via modulation of the nuclear factor-κB signaling pathway" which reported that this study was designed to investigate phosphatase and tensin homolog nuclear translocation and its possible role in rat cortical neuronal damage following oxygen-glucose deprivation in vitro.

9 Aug 2021

Research shows how SARS-CoV-2 variants are evolving towards increased furin cleavage efficiency

The spike protein comprises of two subunits: S1 subunit having the receptor-binding domain (RBD) that helps it to bind to the angiotensin-converting enzyme 2 (ACE2), which is present on the cell surface of the host, and the S2 subunit that helps in the fusion of the cellular membrane and the viral membrane.

9 Aug 2021

Surfactant-coated nanoparticle applications in nanomedicine and food

A group of researchers critically review the use of surfactant-coated nanoparticles in the fields of nanomedicine and food nanotechnology.

8 Aug 2021

New study describes SARS-CoV-2 ExoN enzyme that promotes antiviral resistance

A new study describes the structure of a crucial enzyme present in SARS-CoV-2.

8 Aug 2021

Two monoclonal antibodies broadly neutralize SARS-CoV-2 variants of concern

Researchers in the United States and Canada have described the structural basis and mode of action for two monoclonal antibodies that potently neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

4 Aug 2021

Study investigates the role of eIF4A3 protein in the growth of cancer cells

For a cell to grow and divide, it needs to produce new proteins. This also applies to cancer cells. In a new study published today in Science Advances, researchers at Karolinska Institutet in Sweden have investigated the protein eIF4A3 and its role in the growth of cancer cells.

4 Aug 2021

Cardiac pacemaker could be powered by kinetic energy from the heart

The cardiac pacemaker of the future could be powered by the heart itself, according to researchers at Shanghai Jiao Tong University.

4 Aug 2021

Rigaku Acquires Life Science Imaging Equipment Manufacturer MILabs

Rigaku Corporation (Headquarters: Akishima-shi, Tokyo; President: Toshiyuki Ikeda; "Rigaku"), a leading manufacturer of X-ray analysis equipment, has acquired all issued shares of MILabs B.V. (Headquarters: Houten, The Netherlands; CEO and CSO: Dr. Frederik Beekman; “MILabs”)

From Rigaku Corporation 4 Aug 2021

Next-generation CRISPR tools and therapies improved by modified RNA guides

A new type of gene-editing tool, CRISPR-Cas13, has shown promise in RNA targeting. Previous studies have shown the tool as a potential treatment method for viral diseases, including coronavirus disease (COVID-19).

3 Aug 2021

Study shows COVID-19 organ-specific outcomes depend on anti-spike glycoprotein antibodies

A recent study from the University of Rochester reveals how the biodistribution kinetics and the affinity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for many different organs in the human body can be affected by antibodies targeting viral spike glycoprotein. The paper is currently available on the bioRxiv* preprint server while it undergoes peer review.

3 Aug 2021

“Sybodies” protect against SARS-CoV-2 in hamster model

Researchers in China, The Netherlands, France, and Switzerland have identified synthetic nanobodies or “sybodies” that exhibit potent neutralizing activity against severe acute respiratory syndrome coronavirus (SARS-CoV-2) – the agent responsible for the ongoing coronavirus disease 2019 (COVID-19) pandemic.

3 Aug 2021

Pfizer moves towards an oral anti-COVID-19 therapy

Researchers in the United States have described a novel antiviral agent against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) currently being evaluated in clinical trials as a treatment for coronavirus disease 2019 (COVID-19).

2 Aug 2021

Researchers discover titanium oxide nanoparticle that recognizes SARS-CoV-2’s non-structural protein 1

A pioneering study reports on the interaction of a tailored titanium oxide nanoparticle (NP) with the full-length SARS-CoV-2 non-structural protein 1 (nsp1). This should be of value in developing new therapeutic tools against coronaviruses that act by targeting their proteins. It could also help map the structure of activated proteins.

2 Aug 2021

Could novel biosensors facilitate SARS-CoV-2 antiviral drug research?

An intriguing new study presents a novel approach to biosensor-based evaluation of promising drugs that could inhibit the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) via its 3C-like protease (3CLpro), a viral protease.

2 Aug 2021

Fighting SARS-CoV-2 with nanomedicine

Published in the Journal of Controlled Release, researchers from the German University in Cairo, and the University of Cologne, looked into nano-reformulation of repurposed antiviral and immune-modulating drugs for inhalation therapy against COVID-19. In addition, they focused on how nanomedicine could address the limitations of current therapeutics, enhancing the efficacy, specificity, and safety of such drugs.

1 Aug 2021

Study looks at potent phytocompounds from Himalayan herbs to treat COVID-19

Considering the antiviral activity of medicinal herbs, a new study published in the journal Current Pharmacology Reports focuses on the identification of potent phytochemicals from Himalayan herbs, namely, Rheum emodi, Thymus serpyllum, and Artemisia annua, for the treatment of COVID-19.

1 Aug 2021

Study paves the way to a new drug design concept

Hydrogen peroxide reacts with copper to produce hydroxyl radicals with strong antibacterial properties. However, this requires high copper concentrations because two copper atoms have to come close together, which occurs by chance.

31 Jul 2021